Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1248-1250

  Hanke, B ^a,b   Wein, A ^a   Martus, P ^c   Riedel, C ^a   Voelker, M ^d   Hahn, E G ^a   Schuppan, D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d BAYER AG   (Germany)

Author keywords

CA 19 9; CEA; Chemotherapy; Extracellular matrix; Metastatic colorectal cancer; MMP 2; TIMP 1

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; COLORECTAL CANCER; CONNECTIVE TISSUE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; LIVER METASTASIS; MALE; PREDICTION; PRIORITY JOURNAL; TUMOR GROWTH; TURNOVER TIME;

ADULT; AGED; CELL DIVISION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038147084     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600832     Document Type: Article

References (16)

1. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC for the marimastat pancreatic cancer study group (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19: 3447-3455
2. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392
3. Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, Himmler B, Hohenberger W, Hahn EG, Wein A (2001) CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 12: 221-226
4. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brunner N (2000) High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6: 4292-4299
5. Kähäri VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45
6. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462
7. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274: 21 491-21 494
8. Pellegrini P, Contasta I, Berghella AM, Gargano E, Mammarella C, Adorno D (2000) Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP-1 serum levels for use as markers of pre-invasive to invasive colorectal cancer. Cancer Immunol Immunother 49: 388-394
9. Ropers T, Kroll W, Becka M, Voelker M, Burchardt ER, Schuppan D, Gehrmann M (2000) Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno 1 analyzer. Clin Biochem 33: 7-13
10. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Sadura A, Zee B (2002) Prospective, randomized, double-blind placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20: 4434-4439
11. Schuppan D, Stölzel U, Oesterllng C, Somasundaram R (1995) Serum assays for liver fibrosis. J Hepatol 22 (Suppl 2): 82-88
12. Wein A, Riedel C, Köckerling F, Martus P, Baum U, Brueckl WM, Reck T, Ott R, Hänsler J, Bernatik T, Becker D, Schneider T, Hohenberger W, Hahn EG (2001) Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 12: 1721-1727
13. Wein A, Riedel C, Brückl W, Merkel S, Ott R, Hanke B, Baum U, Fuchs F, Günther K, Reck T, Papadopoulos T, Hahn EG, Hohenberger W (2003) Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-h infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64: 131-138
14. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000) Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer: TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316
15. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG (1995) Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906
16. Zeng ZS, Huang Y, Cohen AM, Guillem JG (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133-3140